射血分数保留心衰的表型异质性:机制见解或影响治疗反应?
本文回顾了HFpEF表型异质性表征的十年努力,认为未能鉴定可靠治疗应答者或揭示新机制通路。相反,入组标准宽泛的大型试验确立了SGLT2抑制剂和MRA的广泛获益,且无亚组效应证据。作者提出内脏肥胖统一假说可能适用于大多数HFpEF患者,复杂表型分型可能不再必要。
要点
- HFpEF复杂表型分型未获可重复结果或发现新治疗通路
- 大型试验中SGLT2抑制剂和MRA获益无亚组效应证据
- 中心性肥胖可能是HFpEF统一机制核心,肥胖患者获益更大
核心结论
- 表型异质性复杂表征未达预期目标,HFpEF领域已有统一假说、广纳患者的成功试验及广泛有效治疗,复杂分型动机或已不再需要
研究设计与样本
- 本文为观点性综述,基于过去十年HFpEF表型多样性表征工作及大型试验结果进行分析
主要发现
- 中性HFpEF试验的亚组分析未能可靠识别治疗应答者
- 蛋白质组学及多表型域无监督聚类分析未获可重复结果(即使同一数据集)
- 未阐明新药开发的新机制通路,也未识别最可能获益患者
- 近期大型试验入组患者总体一致存在多余脂肪,绝大多数有中心性肥胖
- 肥胖患者用有效药物获益特别大
关键数值与推荐
- 大型试验确立SGLT2抑制剂和MRA获益,未见亚组效应
- 若允许III级肥胖或较低利钠肽水平患者入组,观察到的疗效幅度可能更大
临床怎么用
- 支持将内脏肥胖作为HFpEF核心机制,指导临床关注肥胖表型
- 提示临床不必依赖复杂表型分型来选择HFpEF治疗,现有广谱有效药物可广泛使用
局限性
- 本文为观点综述,无原始数据,所提可能性为推测性质
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At a time when there was no unifying hypothesis and no broadly effective treatments for heart failure with a preserved ejection fraction (HFpEF), it was proposed that HFpEF represented a multitude of different disorders. Accordingly, characterization of phenotypic heterogeneity was envisioned as a means of identifying novel causal pathways that could lead to new treatments while simultaneously discerning patients who would selectively benefit from a specific therapy. However, efforts over the past decade to characterize phenotypic diversity in diverse and complex ways have not achieved these goals. Subgroup analyses of neutral HFpEF trials have failed to reliably identify responders to treatments. Neither proteomics nor unsupervised cluster analysis across multiple phenotypic domains has yielded reproducible results (even in the same dataset), elucidated novel mechanistic pathways for new drug development, or identified patients most likely to benefit from treatment. In marked contrast to these efforts to characterize phenotypic heterogeneity, large-scale trials in HFpEF enrolled patients using broad eligibility criteria, and they established the benefits of sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists without evidence for subgroup effects. However, it is noteworthy that patients enrolled in recent large-scale HFpEF trials were characterized by general uniformity with respect to the presence of excess adiposity, with central obesity being a feature of the vast majority of enrolled participants. Of note, patients with obesity showed particularly large benefits when treated with effective drugs for HFpEF. These observations raise the possibility that, if these trials had permitted the participation of patients with class III obesity or with lower natriuretic peptide levels, the magnitude of the observed treatment effects might have been greater than originally reported. These findings are consistent with a central role for visceral adiposity (and the secretion of an altered suite of adipokines) in the pathogenesis of HFpEF. Therefore, because the field of HFpEF has a unifying hypothesis (applicable to the large majority of patients), enrolled a broad population of patients in large-scale trials without subgroup interactions, and has several broadly applicable effective treatments (as is true for heart failure with a reduced ejection fraction), the motivation to characterize phenotypic heterogeneity in HFpEF in complex ways may no longer be supported or needed.
引用
- Packer, Schiattarella, Petrie, et al. Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation. 2026. PMID: 42475435. doi:10.1161/CIRCULATIONAHA.126.079235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。